Citrate pharmacokinetics in acute liver failure clinically ill patients receiving continuous renal replacement therapy
Phase 2
Completed
- Conditions
- Citrate ToxicityRegional Citrate AnticoagulationLiver Failure, AcuteLiver Failure, Acute on ChronicPharmacokineticContinuous Renal Replacement TherapyRegional citrate anticoagulationPharmacokineticsLiver failureCRRTCirrhosis
- Registration Number
- TCTR20210707010
- Lead Sponsor
- Excellence Center for Critical Care Nephrology, King Chulalongkorn Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
1. critically ill ALF or ACLF adult patients with AKI, 2. aged more than 18 y old, 3. receiving CRRT
Exclusion Criteria
1. severe acidosis (pH < 7.1) or severe alkalosis (pH > 7.55), 2. blood transfusion within 24 h prior to the study, 3. use of citrate-containing medications, 4. severe hypocalcemia (serum ionized calcium < 0.8 mmol/L), 5. use of heparin as anticoagulation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Citrate clearance 4 hours Pharmacokinetic study
- Secondary Outcome Measures
Name Time Method Citrate accumulation 4 hours Number of total calcium to ionized calcium ratio more than 2.5 with acidosis with hypocalcemia,Time max 2 hours Time to maximum concentration of citrate at 2 hours,Area under the time curve 4 hours Area under the plasma concentration-time curve of citrate,Change of systemic ionized calcium 4 hours Change in systemic ionized calcium in arterial blood gas during study,Change of ionized magnesium 4 hours Change of ionized magnesium,Change of bicarbonate 4 hours Change of bicarbonate in arterial blood gas during study,Ratio of total calcium to systemic ionized calcium 4 hours Ratio of total calcium to systemic ionized calcium